Fascioscapulohumeral Muscular Dystrophy
7
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Dietary Protein Requirements in Adults With Facioscapulohumeral Muscular Dystrophy
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Neuromuscular Disorder
Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)